Tag: top psychedelics stocks 2021
-
The top 10 most cashed up psychedelics companies right now
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes hundreds of millions of dollars. And that’s only part of the picture. According to Tufts Center for the Study of Drug Development, bringing a new FDA-approved drug…
-
Gavinchuk: I’m not seeing enough nerdy data talk within the psychedelics space
Forget weed crypto First off, most all of those crypto/cannabis hybrid deals were super cringe, and I never saw the point of combining the two, at least not at the scale at which it happened. But psychedelics is a different beast, and tech integrations make a lot more sense than they did with cannabis. It…
-
Cybin (CYBN.N) finishes its first trading day on the NYSE
The NYSE Cybin (CYBN.N) just finished its first trading day on the New York Stock Exchange (NYSE) after announcing the upcoming uplisting last month. It was a less than desirable day for the stock, but it’s really only a blip when factoring in the runup to the NYSE debut. In recent months we have seen…
-
Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin
Mushroom enthusiasts Filament Health (FH.NE) is looking at mushroom compounds far beyond just psilocybin as the company is run by actual mushroom enthusiasts with access to a lot of tools. Filament has the capabilities to experiment and come up with interesting new compounds, extraction methods, and potential future products that probably go far beyond whatever…
-
Mind Cure (MCUR.C) has pivoted a few times, but may finally be onto something with its focus on tech
Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to raise a considerable amount of cash while having its hands in several different buckets, bringing in $23 million CAD on a bought deal back in February. Mind…
-
Bright Minds Biosciences (DRUG.C) is actually really tight
Serotonin over psychedelics Bright Minds Biosciences (DRUG.C) isn’t banking on recreational psychedelics being relevant any time soon, they aren’t selling mushroom powder, and don’t own any ketamine clinics. Rather, they are developing novel therapeutics to improve the lives of people with severe and life-altering diseases with a focus on 5-HT (serotonin) medicines. The company does…
-
What are psychedelics companies like Psyense (PSYG.C), Havn (HAVN.C), Canbud (CBDX.C) and Field Trip (FTRP.C) all doing in Jamaica?
Shroom tea Jamaica is one of the few countries in the world where the sale and consumption of psilocybin is legal, and through my DD, it’s incredibly easy to attain. The country isn’t new to foreigners tripping there, tourists have been visiting the island for decades for its famous magic mushroom teas. For people who…
-
How Cybin (CYBN.NE) is integrating new brain imaging technology with psychedelics
Shamans among the machines In his 1999 lecture titled ‘Shamans Among the Machines’ Terence McKenna pointed out that “as far as people and machines are concerned, it was Ludwig von Bertalanffy who said in his book General Systems Theory: ‘people are not machines, but in every opportunity where they are allowed to behave like machines,…
-
Revive Therapeutics (RVV.C) CEO Michael Frank likes the stock, buys the dip
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or anything, things have been running pretty nicely the past couple of quarters and it was probably time for a correction. Any time a sector emerges this quickly there…